|Bid||23.67 x 800|
|Ask||23.68 x 800|
|Day's Range||23.59 - 23.94|
|52 Week Range||23.05 - 48.77|
|Beta (3Y Monthly)||1.10|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
At Insider Monkey we track the activity of some of the best-performing hedge funds like Appaloosa Management, Baupost, and Tiger Global because we determined that some of the stocks that they are collectively bullish on can help us generate returns above the broader indices. Out of thousands of stocks that hedge funds invest in, small-caps […]
MEDNAX Inc NYSE:MDView full report here! Summary * ETFs holding this stock are seeing positive inflows but are weakening * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for MD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative and may be weakening. The net inflows of $191 million over the last one-month into ETFs that hold MD are among the lowest of the last year and appear to be slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Mednax (MD) delivered earnings and revenue surprises of -8.45% and -5.89%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Sunrise, Florida-based company said it had a loss of $2.81 per share. Earnings, adjusted for one-time gains and costs, were 65 cents per share. The results fell short of Wall Street expectations. The ...
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! After MEDNAX, Inc.'s (NYSE:MD) recent earnings announcement in December 2018...
"October lived up to its scary reputation—the S&P 500 falling in the month by the largest amount in the last 40 years, the only worse Octobers being '08 and the Crash of '87\. For perspective, there have been only 5 occasions in those 40 years when the S&P 500 declined by greater than 20% from […]
Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! The latest earnings release MEDNAX, Inc.'s (NYSE:MD) announced in December 2018 showed that the...
CVS Health Corp, Walgreens Boots Alliance Inc., Mednax Inc. and Amdocs Ltd. have declined to their respective three-year lows
UBS Group AG (UBS), AutoNation Inc. (AN), Mednax Inc. (MD) and Amdocs Ltd. (DOX) have declined to three-year lows. The price of UBS Group shares declined to $11.88 on March 22, which is only 2.3% above the three-year low of $11.61. UBS is a Swiss investment bank and financial services company.
Announcement: Moody's announces completion of a periodic review of ratings of MEDNAX, Inc. New York, March 22, 2019 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of MEDNAX, Inc. and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.